Clinical Use of the Parathyroid Hormone Assay

May 31, 2017 by in ENDOCRINOLOGY Comments Off on Clinical Use of the Parathyroid Hormone Assay

  A Strongly recommend B Recommend C No recommendation D Recommend against I Insufficient evidence Disease      Primary hyperparathyroidism •     Secondary hyperparathyroidism  •    Reoperative hyperparathyroidism •     MEN1  •    Parathyroid carcinoma     •…

read more

History of Parathyroids

May 31, 2017 by in ENDOCRINOLOGY Comments Off on History of Parathyroids

© Springer-Verlag Italia 2016Guido Gasparri, Nicola Palestini and Michele Camandona (eds.)Primary, Secondary and Tertiary HyperparathyroidismUpdates in Surgery10.1007/978-88-470-5758-6_1 1. History of Parathyroids Guido Gasparri1  , Michele Camandona and Nicola Palestini (1) Department of Surgical Sciences, University of Turin, Turin, Italy  …

read more

The Life History of ApoB Lipoprotein Particles

May 31, 2017 by in ENDOCRINOLOGY Comments Off on The Life History of ApoB Lipoprotein Particles

FIGURE 1.1 The apoB48 lipoprotein particle family consists of chylomicrons and chylomicron remnants (CR). Chylomicrons are secreted by intestinal cells following a meal and transport the dietary lipids to target…

read more

The Primary ApoB Dyslipoproteinemias

May 31, 2017 by in ENDOCRINOLOGY Comments Off on The Primary ApoB Dyslipoproteinemias

FIGURE 3.1 3.1 HyperTG NormoapoB This can be due to (Figure 3.1): 1) Increased chylomicron particles   2) Increased chylomicron particles and increased VLDL particles   3) Increased chylomicron and…

read more

ApoB in Cardiovascular Risk Prediction

May 31, 2017 by in ENDOCRINOLOGY Comments Off on ApoB in Cardiovascular Risk Prediction

FIGURE 5.1 The measurement of LDL-C has major limitations, which have not received the attention the issue deserves. If LDL-C is calculated by the Friedewald formula, as it is in…

read more

Secondary ApoB Dyslipoproteinemias

May 31, 2017 by in ENDOCRINOLOGY Comments Off on Secondary ApoB Dyslipoproteinemias

FIGURE 4.1 4.2.1 HyperTG HyperapoB: Increased VLDL and LDL Lipoprotein Particles Pathophysiology of Increased VLDL and LDL Particle Number The most frequently observed atherogenic dyslipoproteinemia in overweight or obese patients…

read more

ApoB Lipoprotein Particles: the preferred Treatment Target in Primary and Secondary Prevention

May 31, 2017 by in ENDOCRINOLOGY Comments Off on ApoB Lipoprotein Particles: the preferred Treatment Target in Primary and Secondary Prevention

Guideline LDL-C mmol/l  Non-HDL-C  apoB   Concentration mmol/l mg/dl NHANES Population percentile Concentration mmol/l mg/dl NHANES population percentile Concentration g/l NHANES population percentile National Lipid Association 197        High risk  < 2,6 < 100…

read more

Coping with Colorectal Cancer

May 8, 2017 by in ONCOLOGY Comments Off on Coping with Colorectal Cancer

21 Coping with Colorectal Cancer Eden R. Stotsky KEY POINTS • Colon and rectal cancers are among the most common adult cancers worldwide, and the number of survivors of colorectal…

read more
Get Clinical Tree app for offline access